Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

9 Meters Biopharma Inc (NMTR)

9 Meters Biopharma Inc (NMTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 331,179
  • Shares Outstanding, K 254,753
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,500 K
  • 60-Month Beta -0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.65
Trade NMTR with:

Options Overview Details

View History
  • Implied Volatility 139.60%
  • Historical Volatility 51.95%
  • IV Percentile 33%
  • IV Rank 12.26%
  • IV High 502.11% on 11/09/20
  • IV Low 88.97% on 06/21/21
  • Put/Call Vol Ratio 1.14
  • Today's Volume 1,809
  • Volume Avg (30-Day) 1,735
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 59,154
  • Open Int (30-Day) 50,614

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.04
  • Number of Estimates 3
  • High Estimate -0.03
  • Low Estimate -0.06
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1129 +24.90%
on 08/24/21
1.4000 -0.71%
on 09/23/21
+0.2600 (+23.01%)
since 08/23/21
3-Month
1.0101 +37.61%
on 08/16/21
1.4200 -2.11%
on 07/08/21
+0.0400 (+2.96%)
since 06/23/21
52-Week
0.6300 +120.63%
on 11/02/20
2.2600 -38.50%
on 02/16/21
+0.6599 (+90.38%)
since 09/23/20

Most Recent Stories

More News
9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference

- Conference Dates: September 27th-30th -

NMTR : 1.3850 (+6.54%)
9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Conference Dates: September 20th-23rd

NMTR : 1.3850 (+6.54%)
9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

- Conference Dates: September 13th-15th -

NMTR : 1.3850 (+6.54%)
9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

- Conference Dates: September 08th-10th -

NMTR : 1.3850 (+6.54%)
9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19

-Study May Proceed Letter Received from FDA Under Investigator IND-

NMTR : 1.3850 (+6.54%)
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021

- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance -

NMTR : 1.3850 (+6.54%)
9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI"

Conference Call Scheduled for August 12, 2021

NMTR : 1.3850 (+6.54%)
Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas. The stock rises 9% post the announcement.

PFE : 44.37 (+0.96%)
BMRN : 79.45 (+0.53%)
ARVN : 92.95 (-0.79%)
NMTR : 1.3850 (+6.54%)
9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity

- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) -

NMTR : 1.3850 (+6.54%)
Thinking about buying stock in Tencent Music Entertainment, Delta Air Lines, Iterum Therapeutics, HP, or 9 Meters Biopharma?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TME, DAL, ITRM, HPQ, and NMTR.

ITRM : 0.5693 (-1.84%)
NMTR : 1.3850 (+6.54%)
DAL : 42.70 (+2.67%)
HPQ : 28.16 (+2.07%)
TME : 7.38 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

9 Meters Biopharma, Inc. is a rare, orphan and unmet needs focused GI company. It's advancing NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for Short Bowel Syndrome, a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported...

See More

Key Turning Points

3rd Resistance Point 1.4765
2nd Resistance Point 1.4133
1st Resistance Point 1.3566
Last Price 1.3850
1st Support Level 1.2367
2nd Support Level 1.1735
3rd Support Level 1.1168

See More

52-Week High 2.2600
Fibonacci 61.8% 1.6373
Fibonacci 50% 1.4450
Last Price 1.3850
Fibonacci 38.2% 1.2527
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar